Stockreport

Epizyme Reports Positive Data on Tazemetostat in Epithelioid Sarcoma from its Phase 2 Trial Cohort at ESMO

Epizyme, Inc.  (EPZM) 
Last epizyme, inc. earnings: 2/24 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: epizyme.com
PDF Updated Efficacy and Safety Data Support Company’s Planned Submission of a New Drug Application for Tazemetostat for Epithelioid Sarcoma in the First Hal [Read more]